A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577.
Marieke PapePauline A J VissersLaurens V BeerepootMark I van Berge HenegouwenSjoerd M LagardeStella MookMarkus MoehlerHanneke W M van LaarhovenRob H A VerhoevenPublished in: Therapeutic advances in medical oncology (2022)
11.0 months). Possible explanations are differences in characteristics, quality of esophageal cancer care, or differential strategies for evaluation of recurrence. In the Netherlands postoperative imaging is not part of the standard follow-up as opposed to the standard postoperative imaging in the CheckMate 577 trial. The difference in postoperative imaging could partially explain the longer disease-free survival observed in our study. Quality and optimization of current treatment modalities remain important aspects of esophageal cancer care.